Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $332,304 — NHP immunized with 10 and 100g of mRNA-1273 encoding the SARS CoV2 had robust neutralizing antibodiy titers following two immunizations. mRNA-1273 induced Th1-biased CD4 T cell responses and low or undetectable Th2 or CD8 T responses. Following an infectious challenge with SARS CoV2 by the intrana…
Anirban Banerjee · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2022 · $12,607,429 — 1) Structure and function of eukaryotic integral membrane enzymes that catalyze protein lipidation - A. Structural and chemical biology of zDHHC palmitoylacyltransferases - Of the different forms of protein lipidation, protein S-acylation, commonly known as protein palmitoylation, is the most prev…
Dima A Hammoud · CLINICAL CENTER · 2022 — Progress: Sars-Cov-2 project: We have started our experiments by developing the LPS lung injury model by administering LPS intratracheally. We are using male and female mice, including WT and ACE2 Transgenic mice. At this stage we are imaging the lung infiltrates and assessing ACE2 levels in the var…
Aleksandra Nita-Lazar · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $1,155 — The focus of the proteomic approach is to identify and quantify viral structural proteins, specifically spike (S) glycoprotein as well as envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein in patient samples. The S protein mediates attachment of the virus to the host cell surfa…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $321,289 — We are developing paramyxovirus vectored vaccines for intranasal immunization against SARS-CoV-2. The vaccine vectors express prefusion-stabilized versions of the SARS-CoV-2 S protein and are designed to be highly attenuated in humans while maintaining a high level of immunogenicity at the primary s…
Dax A Hoffman · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2022 · $2,257,955 — Isomerase regulation of potassium channel trafficking and function. We recently identified a novel molecular cascade initiated by the activation of p38 kinase and subsequent Pin1dependent isomerization of a C-terminal motif (T607) in Kv4.2 that triggers dissociation from its auxiliary subunit DPP6,…
JOHN H KEHRL · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $40,147 — Beta-Coronaviruses are a family of positive-strand enveloped RNA viruses that includes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our recent studies have focused on two SARS-CoV-2 encoded proteins, open reading frame (ORF) 3a and 8. Previous studies of SARS-CoV-1 identified O…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $160,169 — Following the success of our HIV vaccine platform based on co-formulated Env+Gag mRNA in order to produce non-infectious VLPs (Zhang et al., Nat. Med. 27:2234, 2021), in collaboration with Moderna, Inc., we have designed a similar vaccine platform for SARS-CoV-2. The major results obtained include t…
Mark Connors · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $217,764 — Our laboratory is engaged in the study of the immune response to SARS-CoV-2 in two major areas. The first of these is the study of the immune response to natural infection. The second is the response to virus-like particles or replicating recombinant adenovirus type 4 (Ad4) vaccines. We are colla…
Pamela Frischmeyer-Guerrerio · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $612,630 — The SARS-CoV-2 virus has incited a global pandemic leading to profound loss of human life and tremendous economic and social upheaval. The FDA has now approved two mRNA vaccines produced by Pfizer-BioNTech and Moderna that were found to be highly effective in Phase 3 trials at preventing COVID-19. T…
Robert Petrovich · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2022 · $1,352,350 — The protein expression facility (PEF) functions as a support group for the principal investigators at the NIEHS. Our focus is to provide the research groups with a means to generate the proteins they require so that they can perform their experiments. These projects range from generating enough o…
Lesia Dropulic · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $680,544 — This project includes the evaluation of a vaccine candidate targeting SARS-CoV-2, mRNA-1273, that was administered to healthy volunteers in a phase 1 trial (DMID 20-0003). This project also includes the collection of samples for translational immunology research from participants who have been vacci…
Thomas Redmond · NATIONAL EYE INSTITUTE · 2022 · $367,569 — Novel coronavirus SARS-CoV-2, originating at the end of 2019 in Wuhan, China, causes the pandemic coronavirus disease COVID-19 that has had a major public health and economic impact in the USA and the rest of the world since then. The disease is quite heterogeneous and targets internal organs with m…
Alan Koretsky · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · 2022 · $1,663,773 — We have made substantial progress towards Aims 1-5, 7&8. Specifically: a) We have reproducibly fabricated 3 nm iron oxide nanoparticles independently in our own lab. These serve as good T1 MRI contrast agents and have strong T2 contrast properties as well. b) We have developed several camelid VHH a…
eric freed · DIVISION OF BASIC SCIENCES - NCI · 2022 · $247,114 — In a structural and functional analysis of the SARS-CoV-2 S protein that we recently started, we have determined that MARCH8, but not a catalytically inactive MARCH8 mutant, targets the S proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2 for degradation. We also showed that human airway …
di s xia · DIVISION OF BASIC SCIENCES - NCI · 2022 · $111,994 — Lead identification. Based on the well-established principle that the S proteins carry out all the cell entry functions of CoVs, the CoV S spike were incorporated onto a replication defective HIV core, resulting pseudovirions with SARS-CoV-2 S protein expressed on the surface of viral…
DAVID B. WEINER · WISTAR INSTITUTE · 2022 · $1,107,120 — Project 2 Summary There is an urgent need to develop vaccines which induce robust and lasting immunity against current and emerging pathogenic coronaviruses (CoVs). These vaccines must also be immunogenic in elderly patients as they are at increased risk of severe coronavirus disease. Many novel CoV…
Michel C Nussenzweig · ROCKEFELLER UNIVERSITY · 2022 · $1,454,501 — Project Summary The COVID-19 pandemic is currently gripping the world. Aside from the health consequences, the necessary decrease in human activity has resulted in economic losses without modern precedent, especially in the developing world where health care and sanitation were not sufficient even …
Michael S Diamond · WASHINGTON UNIVERSITY · 2022 · $2,161,141 — Project Summary Over the past twenty years, six coronaviruses (CoV) have emerged or expanded their geographic range. The emergent human CoVs with the greatest global impact (SARS-CoV-1, SARS-CoV-2, and MERS-CoV) belong to the Sarbecovirus and Merbecovirus subgenera within the Betacoronavirus genus o…
IRWIN M CHAIKEN · DREXEL UNIVERSITY · 2022 · $343,785 — SUMMARY HIV-1 is the causative agent of AIDS, which remains a global pandemic. The need continues for more effective and broadly active preventive strategies and anti-retroviral therapies to target infectious virus and already- infected cells. In both virus-cell and cell-to-cell infection, the metas…